Co-Diagnostics Analyst Ratings
Co-Diagnostics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 159.43% | HC Wainwright & Co. | $2 → $3 | Maintains | Neutral |
| 08/14/2023 | 72.95% | HC Wainwright & Co. | $3 → $2 | Maintains | Neutral |
| 05/15/2023 | 159.43% | HC Wainwright & Co. | → $3 | Reiterates | Neutral → Neutral |
| 03/20/2023 | 159.43% | HC Wainwright & Co. | $6 → $3 | Downgrades | Buy → Neutral |
| 02/23/2023 | 418.85% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 11/14/2022 | 418.85% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
| 08/15/2022 | 678.28% | HC Wainwright & Co. | $12 → $9 | Maintains | Buy |
| 08/12/2022 | 332.38% | Sidoti & Co. | → $5 | Downgrades | Buy → Neutral |
| 05/16/2022 | 937.7% | HC Wainwright & Co. | $15 → $12 | Maintains | Buy |
| 11/12/2021 | 1197.13% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
| 03/29/2021 | — | Maxim Group | Downgrades | Buy → Hold | |
| 03/26/2021 | 1283.6% | HC Wainwright & Co. | $30 → $16 | Maintains | Buy |
| 12/15/2020 | 2494.26% | HC Wainwright & Co. | $29 → $30 | Maintains | Buy |
| 11/17/2020 | 2407.78% | HC Wainwright & Co. | $33 → $29 | Maintains | Buy |
| 08/14/2020 | 2753.68% | HC Wainwright & Co. | $35 → $33 | Maintains | Buy |
| 05/20/2020 | 2494.26% | Maxim Group | → $30 | Upgrades | Hold → Buy |
| 05/18/2020 | 2926.63% | HC Wainwright & Co. | $20 → $35 | Reiterates | → Buy |
| 03/03/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
| 02/24/2020 | 245.9% | HC Wainwright & Co. | $2 → $4 | Maintains | Buy |
| 04/09/2019 | 72.95% | Maxim Group | → $2 | Initiates Coverage On | → Buy |
| 03/11/2019 | 72.95% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/13/2023 | 159.43% | HC Wainwright & Co. | 2 美元 → 3 美元 | 維護 | 中立 |
| 08/14/2023 | 72.95% | HC Wainwright & Co. | 3 美元 → 2 美元 | 維護 | 中立 |
| 05/15/2023 | 159.43% | HC Wainwright & Co. | → 3 美元 | 重申 | 中性 → 中性 |
| 03/20/2023 | 159.43% | HC Wainwright & Co. | 6 美元 → 3 美元 | 降級 | 買入 → 中性 |
| 02/23/2023 | 418.85% | HC Wainwright & Co. | → 6 美元 | 重申 | → 購買 |
| 11/14/2022 | 418.85% | HC Wainwright & Co. | 9 美元 → 6 美元 | 維護 | 買 |
| 08/15/2022 | 678.28% | HC Wainwright & Co. | 12 美元 → 9 美元 | 維護 | 買 |
| 2022 年 12 月 8 日 | 332.38% | Sidoti & Co. | → 5 美元 | 降級 | 買入 → 中性 |
| 05/16/2022 | 937.7% | HC Wainwright & Co. | 15 美元 → 12 美元 | 維護 | 買 |
| 11/12/2021 | 1197.13% | HC Wainwright & Co. | 16 美元 → 15 美元 | 維護 | 買 |
| 03/29/2021 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 2021 年 3 月 26 日 | 1283.6% | HC Wainwright & Co. | 30 美元 → 16 美元 | 維護 | 買 |
| 2020 年 12 月 15 日 | 2494.26% | HC Wainwright & Co. | 29 美元 → 30 美元 | 維護 | 買 |
| 2020 年 11 月 17 日 | 2407.78% | HC Wainwright & Co. | 33 美元 → 29 美元 | 維護 | 買 |
| 2020 年 8 月 14 日 | 2753.68% | HC Wainwright & Co. | 35 美元 → 33 美元 | 維護 | 買 |
| 05/20/2020 | 2494.26% | Maxim 集團 | → 30 美元 | 升級 | 持有 → 買入 |
| 2020 年 5 月 18 日 | 2926.63% | HC Wainwright & Co. | 20 美元 → 35 美元 | 重申 | → 購買 |
| 2020 年 3 月 3 日 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 2020 年 2 月 24 日 | 245.9% | HC Wainwright & Co. | 2 美元 → 4 美元 | 維護 | 買 |
| 2019 年 9 月 4 日 | 72.95% | Maxim 集團 | → 2 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 11 月 3 日 | 72.95% | HC Wainwright & Co. | → 2 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Co-Diagnostics (CODX)?
協同診斷 (CODX) 的目標價格是多少？
The latest price target for Co-Diagnostics (NASDAQ: CODX) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $3.00 expecting CODX to rise to within 12 months (a possible 159.43% upside). 6 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月13日公佈了Co-Diagnostics（納斯達克股票代碼：CODX）的最新目標股價。該分析公司將目標股價定爲3.00美元，預計CODX將在12個月內升至12個月內（可能上漲159.43％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Co-Diagnostics (CODX)?
分析師對協同診斷 (CODX) 的最新評級是多少？
The latest analyst rating for Co-Diagnostics (NASDAQ: CODX) was provided by HC Wainwright & Co., and Co-Diagnostics maintained their neutral rating.
Co-Diagnostics（納斯達克股票代碼：CODX）的最新分析師評級由HC Wainwright & Co. 提供，Co-Diagnostics 維持中性評級。
When is the next analyst rating going to be posted or updated for Co-Diagnostics (CODX)?
Co-Diagnostics (CODX) 的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Co-Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Co-Diagnostics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Co-Diagnostics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Co-Diagnostics的最新評級是在2023年11月13日公佈的，因此您應該預計下一個評級將在2024年11月13日左右公佈。
Is the Analyst Rating Co-Diagnostics (CODX) correct?
分析師評級聯合診斷 (CODX) 是否正確？
While ratings are subjective and will change, the latest Co-Diagnostics (CODX) rating was a maintained with a price target of $2.00 to $3.00. The current price Co-Diagnostics (CODX) is trading at is $1.16, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的協同診斷（CODX）評級維持不變，目標股價爲2.00美元至3.00美元。Co-Diagnostics（CODX）目前的交易價格爲1.16美元，超出了分析師的預期區間。